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Early use conversion of the HeRO dialysis graft
Earl Schuman, MD, and Amy Ronfeld, RN, Portland, Ore
Although more challenging to place, the HeRO device (Hemosphere Inc, Eden Prairie, Minn) provides the dialysis
access-challenged patient the opportunity to have an upper extremity graft rather than being dependent on a catheter or
requiring a lower extremity access. A major difficulty with the HeRO is the need for a concomitant dialysis catheter until
the graft matures. This has been associated with a large number of bacteremia episodes. Currently available early-access
grafts have patency rates similar to standard polytetrafluoroethylene. We have modified the HeRO insertion technique to
combine its attributes with those of an early-use graft. In the five patients presented in this report, we confirm that this
new technique can give the patient a graft that is functional <72 hours and obviate the need for a concomitant catheter.
This results in an infection-free access over the follow-up period. (J Vasc Surg 2011;53:1742-4.)
t
t
(
c
u
w
t
t
s
R
g
d
f
R
t
H
F
p
T
t
f
m
v
t
b
a
s
t
b
m
r
t
N
i
p
t
DFor dialysis access-challenged patients, the HeRO graft
(Hemosphere Inc, Eden Prairie, Minn) has been shown to
have lower infection rates, improved patency rates, and
improved adequacy of dialysis compared with tunneled
catheters.1 One report suggests they are durable.2 Most
patients receive this device due to a central venous stenosis
that precludes use of an arteriovenous graft or native fistula.
The options left for the patient are a tunneled catheter in
the upper torso or access involving the lower extremities.
The sentinel article by Katzman et al1 describes the
placement technique. The main complication they encoun-
tered in 36 patients was bacteremia, which was most likely
due to a concomitant tunneled catheter that was used until
the HeRO device was matured. In their discussion, the
authors recommend “cannulating the HeRO device as
soon as possible and remove the bridging tunneled dialysis
catheter.”
Early-access dialysis grafts have been shown to have
similar patency rates to standard polytetrafluoroethylene
PTFE,3,4 while decreasing the patient’s exposure to a tun-
neled catheter. We have modified the insertion technique
for the HeRO device to allow early access and avoid the
infectious complications previously reported.
METHODS
This study consisted of a concurrent cohort of patients
in a vascular access practice. Patient data were obtained
with each procedure, with follow-up data gathered during
retrospective review. Patients were accrued into the study
from January 2010 to August 2010.
Standard HeRO devices were placed in a standard
fashion up to the implantation of the graft component.
Central access was obtained, and guidewires were manip-
ulated to the atrium, usually with guiding catheter assis-
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1742ance (Figs 1 and 2). The HeRO outflow component was
hen placed after balloon angioplasty of central stenoses
Figs 3 and 4). The titanium connector portion of the graft
omponent was attached to the outflow component in the
pper chest near the deltopectoral groove (Fig 5). The graft
as transected at the lateral end of the ringed segment of
his connecting section (Fig 6). An early-access graft was
hen sutured to this part of theHeROgraft, tunneled to the
elected artery, and anastomosed in a standard fashion.
emoving the standard graft and suturing the early-use
raft to this device adds10 minutes to the procedure but
oes create a second anastomosis. This graft was then used
or dialysis access in the patient’s next session.
ESULTS
Five patients underwent conversion of a HeRO device
o an early-access graft. Flixene Grafts (Atrium Medical,
udson, NH) were used for four of the five conversions.
or the fifth patient, the HeRO graft was sutured to a
reviously placed PTFE graft that was promptly accessed.
hree grafts were accessed24 hours, one in 48 hours, and
he last one in 72 hours. All were patent and used success-
ully. Four of the five grafts were used at flow rates 300
L/min on their initial dialysis treatment. Occlusion de-
eloped in three grafts at 2 days, 3 days, and 2 months. All
hree patients were chronically hypotensive, with their
lood pressure supported by the use of midodrine. In
ddition, one of the patients also had antiphospholipid
yndrome. Patency was restored in two of these grafts and
hey continue to function at 3 and 6 months after throm-
ectomy. One young woman became agitated and de-
anded that her painful, occluded graft be completely
emoved. This was the only failure in this cohort.
Four of the five early-access HeROs continue to func-
ion at an average of 5.5 months (range, 3-8 months).
one have become infected. Warfarin therapy was started
n one patient with multiple occlusions, with no further
roblems at 6 months of follow-up. All attempts to place
his modification were successful.
ISCUSSION
The HeRO device has been a useful addition to the
ascular access surgeon’s armamentarium. Many patients
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F
i
FFig 2. A stiff guiding catheter wire has been inserted through the
atrium to the inferior vena cava. tig 3. A 10-mm balloon is used for angioplasty. An 8-mm vein
s the minimum diameter for passage of the outflow component.ig 4. The outflow component of the HeRO device is shown in
he mid right atrium.
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June 20111744 Schuman and Ronfeldwho were deemed “catheter-dependent” have an opportu-
nity for graft access with its improved flow, more efficient
dialysis, and a decreased chance of a morbid complication.
Immediate-use grafts have been shown to be efficacious
and safe, with a patency profile similar to PTFE. Combin-
ing these access materials gave us the ability to use the
HeRO for the patient’s next dialysis session without the
need for a concomitant catheter. A similar approach was
used by Vasquez et al5 in their single case of converting an
indwelling catheter to a HeRO while also attaching a
Flixene graft for immediate use.
As described in the Katzman series, the HeRO device
carries a high infection burden when implanted while a
tunneled dialysis catheter is simultaneously in use. They
documented 24 overall infection events, and 7 bacteremias
in 36 patients. The bridging catheters were in place an
Fig 5. The HeRO device is transected lateral to the titanium
connector and the corrugated section of graft.
Fig 6. The HeRO graft has been sutured to an early-use graft
near the shoulder.average of 38 days and were used in 88% of the patients. Shis is clearly a significant risk to the patient. They also
escribe a patient with an atrial clot and pulmonary embo-
ism. It was not clear if that patient’s bridging catheter was
n the upper extremity or in a femoral site.
We also experienced a catastrophic complication when
patient with an indwelling catheter underwent HeRO
lacement on the contralateral side, according to protocol.
hest discomfort developed in the first postoperative week,
nd she was brought to the emergency department. She
uickly became dyspneic and died, despite full resuscitative
fforts. Autopsy showed large thrombus in the superior
ena cava around the HeRO outflow component and tun-
eled catheter with a massive pulmonary embolus. These
wo devices almost occluded her vena cava and led to the
hrombus formation.
No cost analysis was done, but the cost of the additional
raft is more than the cost of a concomitant catheter. If the
atheter were placed as a separate procedure, it would then
emore costly than the graft alone. However, the cost of an
nfectious or thrombotic complication from the catheter,
hich is common, would be far greater than the cost of the
dditional graft.
ONCLUSIONS
The modification of the original insertion technique, as
escribed in this article, will reduce infectious and clotting
vents by eliminating the simultaneous use of the HeRO
nd a dialysis catheter. The uniform success of immediate
ccess was documented in these five patients. Their lack of
nfection events during 3 to 8 months of follow-up con-
rms the premise of Katzman et al that the cause of the
acteremias in their patients was the concomitant tunneled
atheter. By increasing the safety profile of the HeRO, this
echnique can give the implanting surgeon and the patient
ecreased concerns about complications.
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